ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00035880
Recruitment Status : Completed
First Posted : May 7, 2002
Last Update Posted : June 24, 2005
Sponsor:
Collaborator:
Sangstat Medical Corporation
Information provided by:
Abgenix

Brief Summary:
Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.

Condition or disease Intervention/treatment Phase
Graft Vs Host Disease Drug: ABX-CBL Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 95 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease
Study Start Date : October 1999
Study Completion Date : June 2003






Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Recipient of single allogeneic stem cell transplant from any donor type
  • Time post transplant less than 100 days
  • Received no treatment for GVHD other than steroids

Exclusion Criteria:

  • Recipient of second allogeneic stem cell transplant or subsequent lymphocyte product from the donor post transplant
  • IBMTR index less than A
  • Received any murine product in the past
  • Diagnosed with chronic GVHD
  • Received Atgam later than day 10 post transplant
  • Change to prophylactic regimen for acute GVHD within 72 hours of randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00035880


Locations
United States, California
Abgenix, Inc
Fremont, California, United States, 94555
Sponsors and Collaborators
Abgenix
Sangstat Medical Corporation

ClinicalTrials.gov Identifier: NCT00035880     History of Changes
Obsolete Identifiers: NCT00012077
Other Study ID Numbers: ABX-CB-9906
First Posted: May 7, 2002    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: July 2003

Keywords provided by Abgenix:
Acute graft versus host disease
Stem Cell Transplantation

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases